Santhera Pharmaceuticals Holding AG (SWX: SANN)
Switzerland
· Delayed Price · Currency is CHF 7.90
-0.42 (-5.05%)
Nov 21, 2024, 5:31 PM CET
SANN Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 113.59 | 103.41 | 7.47 | -1.6 | 15.01 | 75.38 | Upgrade
|
| Revenue Growth (YoY) | 2100.48% | 1283.84% | - | - | -80.09% | 138.10% | Upgrade
|
| Cost of Revenue | 6.52 | 3.24 | 3.59 | 3.77 | 10.43 | 5.45 | Upgrade
|
| Gross Profit | 107.07 | 100.18 | 3.88 | -5.36 | 4.58 | 69.93 | Upgrade
|
| Selling, General & Admin | 31.28 | 30.97 | 25.42 | 22.06 | 23.91 | 39.28 | Upgrade
|
| Research & Development | 22.7 | 18.67 | 24.33 | 29.72 | 34.23 | 41.24 | Upgrade
|
| Other Operating Expenses | -0.64 | -0.62 | -0.1 | -0.25 | -0.49 | -0.16 | Upgrade
|
| Operating Expenses | 53.34 | 49.02 | 49.65 | 51.53 | 57.65 | 80.37 | Upgrade
|
| Operating Income | 53.73 | 51.16 | -45.77 | -56.89 | -53.08 | -10.44 | Upgrade
|
| Interest Expense | -17.33 | -21.31 | -20.19 | -16.42 | -6.89 | -6.08 | Upgrade
|
| Interest & Investment Income | 0.99 | 0.51 | - | 0 | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.86 | -1.15 | -0.22 | -0.06 | 0.27 | -1.47 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.22 | 7.51 | -0.35 | 5.22 | -7.76 | -0.41 | Upgrade
|
| EBT Excluding Unusual Items | 45.47 | 36.71 | -66.53 | -68.16 | -67.46 | -18.39 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.68 | 0.68 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 17 | 17.68 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -6.21 | - | - | - | Upgrade
|
| Other Unusual Items | - | -0.25 | 2.12 | 13.44 | - | - | Upgrade
|
| Pretax Income | 63.15 | 54.82 | -70.62 | -54.72 | -67.46 | -18.39 | Upgrade
|
| Income Tax Expense | 0.3 | 0.04 | 0.46 | 0.81 | 0.2 | 0.58 | Upgrade
|
| Net Income | 62.86 | 54.78 | -71.08 | -55.53 | -67.66 | -18.97 | Upgrade
|
| Net Income to Common | 62.86 | 54.78 | -71.08 | -55.53 | -67.66 | -18.97 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 6 | 3 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 6 | 3 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 24.61% | 79.29% | 78.31% | 156.61% | 21.15% | 59.49% | Upgrade
|
| EPS (Basic) | 5.89 | 5.18 | -11.67 | -16.25 | -50.81 | -17.26 | Upgrade
|
| EPS (Diluted) | 5.70 | 5.01 | -11.67 | -16.25 | -50.81 | -17.26 | Upgrade
|
| Free Cash Flow | 47.18 | 47.18 | -29.9 | -37.36 | -43.54 | 2.5 | Upgrade
|
| Free Cash Flow Per Share | 4.28 | 4.32 | -4.91 | -10.93 | -32.70 | 2.27 | Upgrade
|
| Gross Margin | 94.26% | 96.87% | 51.93% | - | 30.50% | 92.77% | Upgrade
|
| Operating Margin | 47.30% | 49.47% | -612.42% | - | -353.65% | -13.85% | Upgrade
|
| Profit Margin | 55.34% | 52.97% | -951.10% | - | -450.82% | -25.17% | Upgrade
|
| Free Cash Flow Margin | 41.54% | 45.62% | -400.05% | - | -290.11% | 3.31% | Upgrade
|
| EBITDA | 57.27 | 53.76 | -42.56 | -53.59 | -49.62 | -6.85 | Upgrade
|
| EBITDA Margin | 50.42% | 51.99% | - | - | - | -9.09% | Upgrade
|
| D&A For EBITDA | 3.55 | 2.6 | 3.21 | 3.3 | 3.46 | 3.59 | Upgrade
|
| EBIT | 53.73 | 51.16 | -45.77 | -56.89 | -53.08 | -10.44 | Upgrade
|
| EBIT Margin | 47.30% | 49.47% | - | - | - | -13.85% | Upgrade
|
| Effective Tax Rate | 0.47% | 0.07% | - | - | - | - | Upgrade
|
| Revenue as Reported | 113.59 | 103.41 | 7.47 | -1.6 | 15.01 | 75.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.